Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MARS1 | P56192 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | IARS1 | P41252 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7783167 | 0.82 | TP53 (0.39) | CA1CA2MARS1TP53IARS1 | |
| SCHEMBL7791102 | 0.77 | SIGMAR1 (0.40) | MAPT | |
| SCHEMBL7791789 | 0.76 | MAPT (0.42) | TP53POLBMAPT | |
| SCHEMBL7783151 | 0.72 | HSD17B10 (0.43) | TP53POLBMAPT | |
| SCHEMBL14703885 | 0.68 | CA1 (0.75) | CA1CA2IARS1 | |
| SCHEMBL17212236 | 0.67 | CA1 (0.67) | CA1CA2IARS1 | |
| SCHEMBL28633243 | 0.66 | CA1 (0.65) | CA1CA2POLB | |
| SCHEMBL2742529 | 0.65 | CA1 (0.82) | CA1CA2 | |
| SCHEMBL7792988 | 0.65 | MAPT (0.48) | TP53POLBMAPT | |
| SCHEMBL17214300 | 0.64 | CA1 (0.72) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NEUROGEN CORPORATION | 2001-10-18 | — | — | US | claimed |
| US-6221875-B1 | TREATING FEEDING DISORDERS, OBESITY, BULIMIA NERVOSA OR HYPERTENSION IN A MAMMAL | NEUROGEN CORPORATION | 2001-04-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031758-A1 | Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands | NPY1R, NPY2R, NPY5R | CA1 4120/4885CA2 3542/4885MARS1 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.